Phenotypic and metabolic characterization of the metabolic syndrome in Cartagena de Indias;Caracterización fenotípica y metabólica del síndrome metabólico en Cartagena de Indias

Revista Colombiana de Cardiologia

Volumn 15, Issue 3, 2008, Pages 97-101

  Manzur, Fernando ^a,c   Alvear, Ciro ^a   Alayón, Alicia ^b  

^a UNIVERSIDAD DE CARTAGENA   (Colombia)

^b UNIVERSIDAD DE SAN BUENAVENTURA   (Colombia)

^c Centro de Diagnóstico Cardiológico   (Colombia)

Author keywords

Cardiovascular disease; Diabetes mellitus; Metabolic syndrome; Prevention; Promotion

Indexed keywords

EID: 55349115099     PISSN: 01205633     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rodríguez Porto AL, Sánchez León M, Martínez Valdés LL. Síndrome metabólico. Rev Cub Endocrinol 2002;13(3):238-52.
2. González Sarmiento Enrique, Pascual Calleja I, Laclaustra Gimeno M, Casasnovas Lenguas JA. Síndrome metabólico y diabetes mellitus. Rev Esp Cardiol 2006;5(Supl. D):30-37.
3. Kylin E. Studien uber das hypertonie-hyperglykämie-hyperurikämiesyndrom. Zentralblatt Fuer Innnere Med 1923;44:105-27.
4. Hanefeld M. The metabolic syndrome: Roots, myths and facts. En: Hanefeld M, Leonhardt W, editors. The metabolic syndrome. Jena: Gustav Fisher Verlag; 1997. p. 13-24.
5. Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
6. Albert KG, Kimmet PZ. World Heart Organization Report of a WHO consultation: definition of metabolic syndrome in definition, diagnosis, and classification of diabetes mellitus and its complication. Part 1: diagnosis and classification of diabetes mellitus. Diabetic Medic 1998;15:539-53.
7. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;6:442-3.
8. European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
9. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Finding from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-59.
11. Carr DB, Itzschneider KM, Hull RL et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53(8):2087-94.
12. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, for the Conference Participants. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004;109:433-8.
13. American Association of Clinical Endocrinologist. Code for dismetabolic Syndrome X. Disponible en: www.aace.com.
14. International Diabetes Federation. The IDF Consensus worldwide definition of the metabolic syndrome. Disponible en: www.idf.org.
15. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome a new worldwide definition. Lancet 2005;366:1059-1062.
16. Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart Disease. Arterioscler Thromb Vasc Biol 1999;19:1819-24.
17. Meigs JB. Metabolic syndrome: in search of a clinical role. Diabet Care 2004;27 (11):2761-3.
18. Vasan RS, Sullivan LM, Wilson PW, Sempos CT, Sundstrom J, Kannel WB et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005;142(6):393-402.
19. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123-8.
20. Gimeno Orna JA, Lou Arnal LM, Molinero Herguedas E, Boned JB, Portilla Córdoba DP. Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2. Rev Esp Cardiol 2004;57:507-13.
21. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30(1):8-13.
22. Consenso del grupo de trabajo resistencia a la insulina de la Sociedad Española de Diabetes. La resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a la diabetes tipo 2. Med Clin (Barc) 2002;119:458-63.
23. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110(10):1251-7.
24. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic european men and women. Arch Intern Med 2004;164:1066-76.
25. The metabolic syndrome still lives. Clinical Chemistry Washington 2005;51(8): 1352-54.
26. Villegas A, Botero J, Arango I, Arias S, Toro M. Prevalencia del síndrome metabólico en El Retiro, Antioquia, Colombia. Iatreia 2003;16(4):291-297.